-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Fourth Pharmaceutical’s moxifloxacin hydrochloride tablets have been approved.
Category:
Time：2022-01-24
On January 11, the moxifloxacin hydrochloride tablets (0.4g) developed by Shijiazhuang Sihua Pharmaceutical Co., Ltd. received a drug registration certificate issued by the National Medical Products Administration and are deemed to have passed the evaluation of consistency in quality and efficacy for generic drugs.
At the start of the new year, Shijiazhuang No.4 Pharmaceutical Company has once again delivered good news in its research and development efforts. On January 11, the moxifloxacin hydrochloride tablets (0.4g) developed by Shijiazhuang No.4 Pharmaceutical Co., Ltd. received a drug registration certificate issued by the National Medical Products Administration and are deemed to have passed the evaluation of consistency in quality and efficacy for generic drugs.
Previously, the moxifloxacin hydrochloride sodium injection developed by Shijiazhuang No.4 Pharmaceutical Company received approval from the National Medical Products Administration in 2020 and passed the evaluation of consistency in quality and efficacy for generic drugs. The recent approval of moxifloxacin hydrochloride tablets further strengthens the development of a comprehensive moxifloxacin product line.
It was introduced that moxifloxacin is a fourth-generation quinolone antibacterial agent and a new-generation antibiotic with a broad-spectrum antimicrobial profile. It is primarily used to treat various bacterial infections, including pneumonia, tuberculosis, endocarditis, conjunctivitis (pink eye), and respiratory tract infections.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license